Product Description
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: Fast Track - Endometriosis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GE Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT05623332 | N/A |
Unknown status |
Endometriosis |
2023-12-01 |
|
GE-078-101 | P2 |
Terminated |
Heart Failure |
2012-03-01 |